Q1 2021 Venture Financing Report – A Strong Start To The Year

CL
Cooley LLP

Contributor

Cooley LLP logo
Clients partner with Cooley on transformative deals, complex IP and regulatory matters, and high-stakes litigation, where innovation meets the law. Cooley has nearly 1,400 lawyers across 18 offices in the United States, Asia and Europe, and a total workforce of more than 3,000.
The robust financing environment we saw throughout the latter half of 2020 continued into the first quarter of 2021. Cooley handled 339 disclosable deals in Q1. This is relatively consistent with the...
United States Corporate/Commercial Law
To print this article, all you need is to be registered or login on Mondaq.com.

The robust financing environment we saw throughout the latter half of 2020 continued into the first quarter of 2021. Cooley handled 339 disclosable deals in Q1. This is relatively consistent with the prior quarter, but with an increase to more than $18.8 billion of invested capital – a record for this report, which has been published for more than 15 years.

During Q1, median pre-money valuations increased across substantially all deal stages, with only seed-stage transactions seeing relatively flat valuations compared to the prior quarter. Of note, the percentage of Q1 transactions with a median pre-money valuation greater than $100 million reached 40% of deals, a jump from prior quarters. As another signal of the continued strength of the financing environment, the percentage of up rounds again reached 93% of all deals, consistent with Q4 2020.

Deal terms continued to favor companies. In Q1, the percentage of deals using full participating liquidation preferences remained low at fewer than 6% of transactions. Additionally, the data pointed to decreases in recapitalizations and tranched deals.

Spotlight on life sciences

In Q1, Cooley handled 77 disclosable life sciences company financings representing more than $4.8 billion of invested capital, a record high for this report. As we witnessed in Q4 2020, deal sizes continued to surge. In Q1, the average life sciences deal size was $62.5 million, dwarfing the Q4 2020 average of $40 million. Of note, the percentage of life sciences deals structured in tranches again dropped to just 13% of transactions, continuing a trend seen in prior quarters. To view more details on life sciences trends, use the "Life Sciences" filter in our interactive data visualization tool.

Spotlight on tech

Cooley handled 184 disclosable technology company financings representing more than $9.6 billion of invested capital in Q1, marking a surge from prior quarters. Technology company deals represented more than 54% of our disclosable transactions in the quarter. As a signal of investor optimism and company-favorable terms, more than 93% of technology company financings were up rounds during the quarter. To view more details on technology sector trends, use the "Technology" filter in our interactive data visualization tool.

Visit Cooley GO to view the interactive visualization

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

See More Popular Content From

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More